.rll-youtube-player .play{--wpr-bg-582b3023-13f5-4e85-a525-5b0a51a1cfcc: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Ingeniorx

IngenioRx

Jan 31, 2019

Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal

Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles

Feb 12, 2025

Newsletter/Whitepaper

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

IngenioRx

Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal

Editor Picks